Skip to content

All Press Releases

PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY – 31 DECEMBER 2024)

Malmö, February 27, 2025 PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2024. The report can be found on the Company's website: https://pilapharma.com/investors/finansiell-information/ SUMMARY OF YEAR-END REPORT  SECOND HALF YEAR (1 JULY- 31 DECEMBER 2024) Operating income amounted to TSEK 107 (366) The operating result (EBIT) totalled to TSEK -…

Read more

PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A

Malmö, February 24, 2025 PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled H2 Report event in the coming week: ___________Stokk.io Online Webinar - H2 Report (ONLINE)Thursday, February 27, 2025 from 15:00 CET __________CEO Gustav H. Gram will elaborate on the company's second half-year report for 2024 and answer questions about PILA PHARMA and…

Read more

PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY

Malmö, 18 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice, establishing preclinical proof-of-concept. The hypothesis is…

Read more

Contact us

Subscription for press releases
Back To Top